Top

Published in:

01-08-2012

The Efficiency of Proanthocyanidin in an Experimental Pulmonary Fibrosis Model: Comparison with Taurine

Authors: Yetkin Agackiran, Husamettin Gul, Ersin Gunay, Nalan Akyurek, Leyla Memis, Sibel Gunay, Yusuf Sinan Sirin, Tayfun Ide

Published in: Inflammation | Issue 4/2012

Abstract

Pulmonary fibrosis (PF) is a progressive fatal disorder. Bleomycin (BLM) is a widely used chemotherapeutic agent causing PF. Numerous agents have been investigated to prevent the progression of PF so far, but there is still a need to find more efficacious agents. Proanthocyanidin (PA) is a strong antioxidant, the main ingredient of grape seed extract. Since PA is ready for use in practice, we aimed to compare the preventive effect of PA in comparison with taurine (Tau) in BLM-induced PF. Forty Wistar male albino rats were used in the study and were divided into four groups: group 1, control; group 2, BLM-induced PF group; group 3, BLM-induced PF and treated with PA group; and group 4, BLM-induced PF and treated with Tau group. Treatments were begun 10 days before and continued 21 days after BLM injection. PA and Tau effectively inhibited inflammation, edema, severity of fibrosis, fibrosis extension, inflammatory cell accumulation, iNOS staining, and hydroxyproline level as well (p < 0.05). Total histological scores of the PA group were similar to the control group; Tau was significantly higher than the control group but lower than the BLM group (p < 0.05). We believe that PA could be a new treatment choice for PF, but further studies need to be conducted to verify the findings of the current study.

Panos, R.J., R.L. Mortenson, S.A. Niccoli, and T.E. King Jr. 1990. Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment. American Journal of Medicine 88: 396–404.PubMedCrossRef

Kelley, J. 1990. Cytokines of the lung. American Review of Respiratory Disease 141: 765–788.PubMedCrossRef

Manoury, B., S. Nenan, O. Leclerc, I. Guenon, E. Boichot, J.M. Planquois, et al. 2005. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respiratory Research 6: 11.PubMedCrossRef

Morcillo, E.J., J. Estrela, and J. Cortijo. 1999. Oxidative stress and pulmonary inflammation: Pharmacological intervention with antioxidants. Pharmacological Research 40: 393–404.PubMedCrossRef

Nakatani-Okuda, A., H. Ueda, S. Kashiwamura, A. Sekiyama, A. Kubota, Y. Fujita, et al. 2005. Protection against bleomycin-induced lung injury by IL-18 in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 289: L280–L287.PubMedCrossRef

Caspary, W.J., D.A. Lanzo, and C. Niziak. 1982. Effect of deoxyribonucleic acid on the production of reduced oxygen by bleomycin and iron. Biochemistry 21: 334–338.PubMedCrossRef

Moeller, A., K. Ask, D. Warburton, J. Gauldie, and M. Kolb. 2008. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? The International Journal of Biochemistry & Cell Biology 40: 362–382.CrossRef

Bentivegna, S.S., and K.M. Whitney. 2002. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food and Chemical Toxicology 40: 1731–1743.PubMedCrossRef

Shao, Z.H., L.B. Becker, T.L. Vanden Hoek, P.T. Schumacker, C.Q. Li, D. Zhao, et al. 2003. Grape seed proanthocyanidin extract attenuates oxidant injury in cardiomyocytes. Pharmacological Research 47: 463–469.PubMedCrossRef

10.

Yanarates, O., A. Guven, A. Sizlan, B. Uysal, O. Akgul, A. Atim, et al. 2008. Ameliorative effects of proanthocyanidin on renal ischemia/reperfusion injury. Renal Failure 30: 931–938.PubMedCrossRef

11.

Eraslan, G., S. Saygi, D. Essiz, A. Aksoy, H. Gul, and E. Macit. 2007. Evaluation of aspect of some oxidative stress parameters using vitamin E, proanthocyanidin and N-acetylcysteine against exposure to cyfluthrin in mice. Pesticide Biochemistry and Physiology 88: 43–46.CrossRef

12.

Fitzpatrick, D.F., R.C. Fleming, B. Bing, D.A. Maggi, and R.M. O'Malley. 2000. Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. Journal of Agricultural and Food Chemistry 48: 6384–6390.PubMedCrossRef

13.

Sano, T., E. Oda, T. Yamashita, A. Naemura, Y. Ijiri, J. Yamakoshi, et al. 2005. Anti-thrombotic effect of proanthocyanidin, a purified ingredient of grape seed. Thrombosis Research 115: 115–121.PubMedCrossRef

14.

Bagchi, D., C.K. Sen, S.D. Ray, D.K. Das, M. Bagchi, H.G. Preuss, et al. 2003. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutation Research 523–524: 87–97.PubMedCrossRef

15.

Ferguson, P.J., E.M. Kurowska, D.J. Freeman, A.F. Chambers, and J. Koropatnick. 2006. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutrition and Cancer 56: 86–94.PubMedCrossRef

16.

Miyazaki, T., M. Karube, Y. Matsuzaki, T. Ikegami, M. Doy, N. Tanaka, et al. 2005. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. Journal of Hepatology 43: 117–125.PubMedCrossRef

17.

Schuller-Levis, G., R.E. Gordon, C. Wang, S.Y. Park, and E. Park. 2009. Protection of bleomycin-induced fibrosis and inflammation by taurine. International Immunopharmacology 9: 971–977.PubMedCrossRef

18.

Yucel, O., Z.I. Kunak, E. Macit, A. Gunal, A. Gozubuyuk, H. Gul, et al. 2008. Protective efficacy of taurine against pulmonary edema progression: Experimental study. Journal of Cardiothoracic Surgery 3: 57.PubMedCrossRef

19.

Chaudhary, N.I., A. Schnapp, and J.E. Park. 2006. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. American Journal of Respiratory and Critical Care Medicine 173: 769–776.PubMedCrossRef

20.

Cortijo, J., M. Cerda-Nicolas, A. Serrano, G. Bioque, J.M. Estrela, F. Santangelo, et al. 2001. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. European Respiratory Journal 17: 1228–1235.PubMedCrossRef

21.

Hsu, S.M., L. Raine, and H. Fanger. 1981. Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. Journal of Histochemistry and Cytochemistry 29: 577–580.PubMedCrossRef

22.

Woessner Jr., J.F. 1961. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Archives of Biochemistry and Biophysics 93: 440–447.PubMedCrossRef

23.

Demedts, M., A.U. Wells, J.M. Antó, U. Costabel, R. Hubbard, P. Cullinan, H. Slabbynck, G. Rizzato, V. Poletti, E.K. Verbeken, M.J. Thomeer, J. Kokkarinen, J.C. Dalphin, and A.N. Taylor. 2001. Interstitial lung diseases: An epidemiological overview. The European Respiratory Journal. Supplement 32: 2s–16s.PubMed

24.

Chen, F., L. Gong, L. Zhang, H. Wang, X. Qi, X. Wu, et al. 2006. Short courses of low dose dexamethasone delay bleomycin-induced lung fibrosis in rats. European Journal of Pharmacology 536: 287–295.PubMedCrossRef

25.

Hagiwara, S.I., Y. Ishii, and S. Kitamura. 2000. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. American Journal of Respiratory and Critical Care Medicine 162: 225–231.PubMed

26.

Bouros, D., K.M. Antoniou, A. Tzouvelekis, and N.M. Siafakas. 2006. Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Biological Therapy 6: 1051–1060.PubMedCrossRef

27.

Wang, Q., D.M. Hyde, P.J. Gotwals, and S.N. Giri. 2002. Effects of delayed treatment with transforming growth factor-beta soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters. Experimental Lung Research 28: 405–417.PubMedCrossRef

28.

Daba, M.H., A.A. Abdel-Aziz, A.M. Moustafa, A.A. Al-Majed, O.A. Al-Shabanah, and H.A. El-Kashef. 2002. Effects of l-carnitine and ginkgo biloba extract (EG b 761) in experimental bleomycin-induced lung fibrosis. Pharmacological Research 45: 461–467.PubMedCrossRef

29.

Jakubzick, C., E.S. Choi, B.H. Joshi, M.P. Keane, S.L. Kunkel, R.K. Puri, et al. 2003. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. Journal of Immunology 171: 2684–2693.

30.

Wang, Q., M.A. Hollinger, and S.N. Giri. 1992. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment. Journal of Pharmacology and Experimental Therapeutics 262: 127–132.PubMed

31.

Blaisdell, R.J., and S.N. Giri. 1995. Mechanism of antifibrotic effect of taurine and niacin in the multidose bleomycin-hamster model of lung fibrosis: Inhibition of lysyl oxidase and collagenase. Journal of Biochemical Toxicology 10: 203–210.PubMedCrossRef

32.

Schuller-Levis, G.B., R.E. Gordon, E. Park, K.J. Pendino, and D.L. Laskin. 1995. Taurine protects rat bronchioles from acute ozone-induced lung inflammation and hyperplasia. Experimental Lung Research 21: 877–888.PubMedCrossRef

33.

Gurujeyalakshmi, G., Y. Wang, and S.N. Giri. 2000. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 4: 399–411.PubMedCrossRef

34.

Yildirim, Z., N. Kilic, C. Ozer, A. Babul, G. Take, and D. Erdogan. 2007. Effects of taurine in cellular responses to oxidative stress in young and middle-aged rat liver. Annals of the New York Academy of Sciences 1100: 553–561.PubMedCrossRef

35.

Ekremoglu, M., N. Turkozkan, H. Erdamar, Y. Kurt, and H. Yaman. 2007. Protective effect of taurine on respiratory burst activity of polymorphonuclear leukocytes in endotoxemia. Amino Acids 32: 413–417.PubMedCrossRef

36.

Guz, G., E. Oz, N. Lortlar, N.N. Ulusu, N. Nurlu, B. Demirogullari, et al. 2007. The effect of taurine on renal ischemia/reperfusion injury. Amino Acids 32: 405–411.PubMedCrossRef

37.

Gurujeyalakshmi, G., Y. Wang, and S.N. Giri. 2000. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kappaB in mice. Journal of Pharmacology and Experimental Therapeutics 293: 82–90.PubMed

38.

Nobili, S., D. Lippi, E. Witort, M. Donnini, L. Bausi, E. Mini, et al. 2009. Natural compounds for cancer treatment and prevention. Pharmacological Research 59: 365–378.PubMedCrossRef

39.

Salah, N., N.J. Miller, G. Paganga, L. Tijburg, G.P. Bolwell, and C. Rice-Evans. 1995. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Archives of Biochemistry and Biophysics 322: 339–346.PubMedCrossRef

40.

Rice-Evans, C.A., N.J. Miller, and G. Paganga. 1996. Structure–antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biology & Medicine 20: 933–956.CrossRef

41.

Phuwapraisirisan, P., P. Sowanthip, D.H. Miles, and S. Tip-pyang. 2006. Reactive radical scavenging and xanthine oxidase inhibition of proanthocyanidins from Carallia brachiata. Phytotherapy Research 20: 458–461.PubMedCrossRef

42.

Bagchi, D., A. Garg, R.L. Krohn, M. Bagchi, M.X. Tran, and S.J. Stohs. 1997. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Research Communications in Molecular Pathology and Pharmacology 95: 179–189.PubMed

43.

Rodriguez, L.O., and S.M. Hecht. 1982. Iron(II)-bleomycin. Biochemical and spectral properties in the presence of radical scavengers. Biochemical and Biophysical Research Communications 104: 1470–1476.PubMedCrossRef

44.

Aruoma, O.I., B. Sun, H. Fujii, V.S. Neergheen, T. Bahorun, K.S. Kang, et al. 2006. Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials. BioFactors 27: 245–265.PubMedCrossRef

45.

Dedon, P.C., and I.H. Goldberg. 1992. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chemical Research in Toxicology 5: 311–332.PubMedCrossRef

46.

Sheu, S.J., N.C. Liu, and J.L. Chen. 2010. Resveratrol protects human retinal pigment epithelial cells from acrolein-induced damage. Journal of Ocular Pharmacology and Therapeutics 26: 231–236.PubMedCrossRef

47.

Chen, Z.Y., P.T. Chan, K.Y. Ho, K.P. Fung, and J. Wang. 1996. Antioxidant activity of natural flavonoids is governed by number and location of their aromatic hydroxyl groups. Chemistry and Physics of Lipids 79: 157–163.PubMedCrossRef

48.

Quesada, I.M., J.M. Del Bas, C. Blade, A. Ardevol, M. Blay, M.J. Salvado, et al. 2007. Grape seed procyanidins inhibit the expression of metallothione in genes in human HepG2 cells. Genes and Nutrition 2: 105–109.PubMedCrossRef

49.

Saleh, D., P.J. Barnes, and A. Giaid. 1997. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 155: 1763–1769.PubMed

50.

Kalayarasan, S., N. Sriram, and G. Sudhandiran. 2008. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: Critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sciences 82: 1142–1153.PubMedCrossRef

51.

Yildirim, Z., Y. Turkoz, M. Kotuk, F. Armutcu, A. Gurel, M. Iraz, et al. 2004. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11: 156–165.PubMedCrossRef

52.

Shah, V., and P.S. Kamath. 2003. Nitric oxide in liver transplantation: Pathobiology and clinical implications. Liver Transplantation 9: 1–11.PubMedCrossRef

53.

Germano, D., P. Blyszczuk, A. Valaperti, G. Kania, S. Dirnhofer, U. Landmesser, et al. 2009. Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 179: 939–949.PubMedCrossRef

Title: The Efficiency of Proanthocyanidin in an Experimental Pulmonary Fibrosis Model: Comparison with Taurine
Authors: Yetkin Agackiran
Husamettin Gul
Ersin Gunay
Nalan Akyurek
Leyla Memis
Sibel Gunay
Yusuf Sinan Sirin
Tayfun Ide
Publication date: 01-08-2012
Publisher: Springer US
Published in: Inflammation / Issue 4/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-012-9453-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Efficiency of Proanthocyanidin in an Experimental Pulmonary Fibrosis Model: Comparison with Taurine

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Plasma Melatonin and Urinary 6-Hydroxymelatonin Levels in Patients with Pulmonary Tuberculosis

Downregulation of miR-27a* and miR-532-5p and Upregulation of miR-146a and miR-155 in LPS-induced RAW264.7 Macrophage Cells

A Novel Combination of Methotrexate and Epigallocatechin Attenuates the Overexpression of Pro-inflammatory Cartilage Cytokines and Modulates Antioxidant Status in Adjuvant Arthritic Rats

Connexin43 Modulation Inhibits Scarring in a Rabbit Eye Glaucoma Trabeculectomy Model

Bacterial Cell Wall Constituents Induce Hepcidin Expression in Macrophages Through MyD88 Signaling

Lipopolysaccharide-Induced Proliferation of the Vasa Vasorum in a Rabbit Model of Atherosclerosis as Evaluated by Contrast-Enhanced Ultrasound Imaging and Histology

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page